Newsroom

Newsroom

July, 2025



Regeneron Joins PETAL Consortium as a Funding Partner for Our Pathology

Initiative!

We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma.



Regeneron Joins PETAL Consortium as a Funding Partner for Our Pathology

Initiative!

We are thrilled to announce that Regeneron Pharmaceuticals has awarded an educational grant to support PETAL Consortium’s central pathology review initiative, which leverages digital pathology to ensure the consistent and precise diagnosis of peripheral T-cell lymphoma.


Josie Ford was interviewed by Blood Cancers Today!

We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.

Josie Ford was interviewed by Blood Cancers Today!

We're excited to share that Josie Ford was interviewed by Blood Cancers Today about her recently published study in Blood Advances, which investigates the efficacy of the drug combination duvelisib and romidepsin in patients with rare and aggressive blood cancers.


Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer

In this research spotlight, learn about Josie Ford’s recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.


Research Spotlight: Study Demonstrates Drug Combination is Well-Tolerated, Safe and Effective for Patients with Aggressive Blood Cancer

In this research spotlight, learn about Josie Ford’s recent publication on a novel drug combination for lymphoma. She shares how the team's findings could shape future approaches to care for patients with aggressive blood cancers.

Real-World Data Study Led by Dr. Salvia Jain Highlights Promising Treatment for Aggressive Blood Cancer

A new study led by PETAL investigator Dr. Salvia Jain demonstrates that a combination of two blood cancer medications is well tolerated, safe, and effective for patients with aggressive blood cancers who do not respond to standard therapy. The research, based on real-world data, is now featured in the Mass General Brigham Newsroom.

June, 2025



Founder and Principal investigator of the PETAL Consortium


In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of the PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.

Founder and Principal investigator of the PETAL Consortium

In this Q&A, meet Dr. Salvia Jain–founder and principal investigator of the PETAL Consortium–as she shares how her journey in medicine began and what inspired her to focus on blood cancer research.

May, 2025

PETAL Consortium Featured in ASCO Post!

We are excited to share that PETAL Consortium is featured in the ASCO Post! The article highlights our groundbreaking study, which reveals how a specific sequence of therapies can significantly improve survival rates for patients with relapsed/refractory T- and NK-cell lymphomas. By leveraging global data from PETAL, we are moving closer to refining treatment strategies and providing new hope for patients with limited treatment options.


PETAL Research Featured in Mass General Brigham News


Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.

PETAL Research Featured in Mass General Brigham News

Our recent publication in the British Journal of Haematology has been featured by Mass General Brigham. The news release underscores the PETAL Consortium’s innovative and impactful research in guiding personalized treatment strategies for relapsed and refractory T- and NK-cell lymphomas.

Read the press release


Forecasting Optimal Treatments in Relapsed/Refractory Mature T- and NK-Cell LymphomasThe PETAL Consortium’s latest paper published in the British Journal of Haematology.





We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!


We are thrilled that our clinical researcher Caroline MacVicar has been accepted to and plans on attending medical school at Uniformed Services University (USU). Congratulations!





We are delighted to congratulate Dhruv Mistry, a key PETAL team member, on earning his M.B.B.S. degree. We cannot wait to see his career unfold.


We are delighted to congratulate Dhruv Mistry, a key PETAL team member, on earning his M.B.B.S. degree. We cannot wait to see his career unfold.


March, 2025

PETAL Consortium at the TCLF 2025 shared their ongoing projects and work through multiple compelling oral and poster presentations.


We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.


We are excited to share that our latest manuscript Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: a global PETAL Consortium study manuscript has been accepted for publication in the British Journal of Haematology.

February, 2025

MGH the founding site will be participating in the phase III trial of Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.

An inspiring story shared by our PETAL patient on how Specialized Expertise Transformed a Critical Setback From Peripheral T-cell Lymphoma Into Hope

January, 2025

Blood Cancers Today spoke with researchers from the Salvia Jain Lab to learn more about the goals and initiatives of the PETAL Consortium. Leora Boussi, MD, Angela Koh, and Jessy Xinyi Han discuss their study of a novel scoring system using one of the largest international global cohorts of 925 patients with relapsed or refractory mature T-cell and NK-cell lymphomas.

PETAL has been prominently featured in the MGH Cancer Center Curtain Raiser and the Mass General Brigham Cancer Center newsletter, which reaches over 20,000 individuals across academia, industry, and other fields. We are excited to share key updates on our research with this wide audience.

We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment


PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.

PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.

September, 2024


Mass General Cancer Center organized a 5k Run-Walk where the PETAL team along with the whole Cancer Center was running for a cause. Where we raised awareness and funds to support our research with the help, support and dedication of our patients, families and friends who joined us for a cause.

Mass General Cancer Center organized a 5k Run-Walk where the PETAL team along with the whole Cancer Center was running for a cause. Where we raised awareness and funds to support our research with the help, support and dedication of our patients, families and friends who joined us for a cause.


PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment

PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment

June, 2024


PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations

PETAL Consortium @TCLF 2024 excited to share our work through many oral and poster presentations